Trial Profile

Long-term safety and efficacy of Cytori Cell Therapy for the treatment of refractory perianal fistula in Crohn's disease

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 20 Jan 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ECCS 50 (Primary)
Indications Crohn's disease; Fistula
Focus Adverse reactions

Most Recent Events

06 Feb 2019 New trial record
31 Jan 2019 According to a Cytori Therapeutics media release, this study was conducted by a team of investigators from the Departments of Gastroenterology, Digestive Surgery, Plastic Surgery, and Cell Therapy of the Assistance Publique Hopitaux de Marseille (APHM), Aix Marseille University, France.
31 Jan 2019 According to a Cytori Therapeutics media release, results from this trial were published in journal of the American Gastroenterological Association, Gastroenterology,

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com